Overview
Lobbying Costs
150,000€
Financial year: Jan 2019 - Dec 2019
Lobbyists (Full time equivalent)
1 Fte (3)
Lobbyists with EP accreditation
0
High-level Commission meetings
1
Lobbying Costs over the years
-
Info
European Biopharmaceutical Enterprises (EBE)
EU Transparency Register
768792210017-73 First registered on 30 Oct 2012
Goals / Remit
The mission of “European Biopharmaceutical Enterprises” (EBE) is to:
Represent biopharmaceutical companies of all sizes operating in Europe in the formulation of policies at global and European levels.
Focus on enhancing emerging healthcare technologies and promoting science innovation in Europe via expertise in:
• Innovation eco-system and funding models
• Emerging biotech & science - regulatory advancement and advocacy
Contribute industry expertise to the development of new regulatory frameworks, guidelines and standards of relevance to biopharmaceuticals.
Promote the exchange of good practices to foster the development of safe, efficacious and high-quality medicines.
Increase awareness of the sector, its products and the tangible benefits that biopharmaceuticals bring to patients and society worldwide.
Support the business development of member companies, especially SMEs, through advice, networking, training and educational opportunities.
Facilitate information exchange and communications between all stakeholders within the field of biopharmaceuticals through EBE acting as resource centre.
Goal A – Public Affairs
To represent the research-based biopharmaceutical industry operating in Europe in the promotion and formulation of policies creating a favourable scientific, business and regulatory environment, thanks to building and communicating common industry positions through direct representation to key stakeholders at European and global levels.
Goal B – Regulatory & Technical Affairs
To contribute industry expertise to the development of new regulatory frameworks, guidelines and standards of relevance to biopharmaceutical companies operating in Europe and to promote the exchange of good practices fostering the development of safe, efficacious and high-quality medicines.
Goal C – Business Development Support Services
To support the business development of member companies, especially small & medium-sized enterprises, through the provision of quality membership services including advice, networking, training and educational opportunities.
Goal D – Information and Communication
To increase awareness of the industry sector, its products and the tangible benefits that biopharmaceuticals bring to patients and society worldwide. Facilitate information exchange and communications between all stakeholders in the biopharmaceuticals field through EBE acting as resource centre.
Goal E – Membership Growth
To continuously develop a strong membership base composed of large pharmaceutical corporations, biotechnology companies and SMEs that will strengthen the sector’s representation and the association’s expertise & influence in Europe and further afield.Main EU files targeted
EBE tracks and provides input as required on all EU policy initiatives and legislation relating to therapeutic biological medicinal products, advanced therapies, and personalised medicines as well as supporting a viable environment for innovative SMEs in biopharma.
Address
Head Office
rue du Trône, 108
Bruxelles 1050
BELGIUM -
People
Total lobbyists declared
3
Employment time Lobbyists 50% 1 25% 2 Lobbyists (Full time equivalent)
1
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
These three persons spent between 25 and 50% of their time in activities falling under the scope of the Transparency Register. The EBE scope of activities is wider than activities falling under the scope of the Transparency register.
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Trade and business associations
-
Networking
Affiliation
EBE operated as a specialised group within the European Federation of Pharmaceutical Industries and Associations – EFPIA-, which operates as the representative organisation of the pharmaceutical industry in Europe. EBE is a member of the European Alliance for Personalised Medicines (EAPM).
Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2019 - Dec 2019
Lobbying costs for closed financial year
150,000€
Other financial info
EBE was funded by membership contributions.
-
EU Structures
Groups (European Commission)
Medical Device Coordination Group#X03565 #http://ec.europa.eu/transparency/regexpert/index.cfm?do=groupDetail.groupDetail&groupID=3565 #Observer #C#11 - In vitro Diagnostic Medical Devices (IVD)#06 - Borderline and Classification (B&C)#03 - Clinical Investigation and Evaluation (CIE)#07 - New Technologies#04 - Post-Market Surveillance and Vigilance (PMSV)#02 - Standards
Groups (European Parliament)
None
Communication activities
Events with European Institutions and other relevant partners, and publications in respect of biological medicines, advanced therapies and personalised medicines (including diagnostics), as well as the European funding system for innovation in biopharma and support SMEs.
Other activities
EBE interacts on an ad hoc basis with representatives from the EU institutions to support policies and activities that improve healthcare at EU level. EBE regularly covers Committee debates at the European Parliament and attends public hearings, conferences, and roundtables relevant to EBE. EBE also meets with MEPs and assistants and relevant Commission services and the EMA.
Meetings
Meetings
1 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 22 Jun 2016 Location Brussels Subject Advanced therapy medicinal products Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Annika Nowak (Cabinet member)